Bruna J, et al. - The target of this trial was to examine the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn) in patients with colorectal cancer. The significant observations made were as follows: 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, respectively). Intermittent therapy with MR309 was linked with reduced acute oxaipn and higher oxaliplatin exposure. A potential neuroprotective role for chronic cumulative oxaipn was brought to the limelight. MR309 demonstrated an acceptable safety profile.